Good question
It does say in the announcement …
The proposed trial will explore the safety, tolerability and efficacy of a combination of narmafotinib with the chemotherapy regime FOLFIRINOX.
So Presumably not … as the wording says, explore safety tolerability and efficacy
As we know efficacy was not officially tested in the Australian phase 1b trail …
.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-25
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $35.82M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 9.9¢ | $86.01K | 854.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 800000 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 43790 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| ATX (ASX) Chart |